A growing number of experimental compounds that can inhibit GPX4 to induce ferroptosis in cancer cells and/or certain normal cells have been identified, such as RSL3, withaferin A, altretamine, ML210, ML162 and some diverse pharmacological inhibitor (DPI) compounds, and these ferroptosis inducers (FINs) inhibit GPX4 activity by covalently and irreversibly binding the selenocysteine (Sec) in its active site, resulting in the buildup of lipid peroxides, ultimately culminating in ferroptosis198. This evidence concerns the gene GPX4 and cancer.